Paradigm Biopharmaceuticals Future Growth
Future criteria checks 3/6
Paradigm Biopharmaceuticals is forecast to grow earnings at 105.3% per annum. EPS is expected to grow by 104.6% per annum.
Key information
105.3%
Earnings growth rate
104.6%
EPS growth rate
Biotechs earnings growth | 21.3% |
Revenue growth rate | n/a |
Future return on equity | 15.4% |
Analyst coverage | Low |
Last updated | 18 Oct 2023 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2023 | 0 | -69 | -78 | -78 | N/A |
9/30/2023 | 0 | -60 | -62 | -62 | N/A |
6/30/2023 | 0 | -52 | -45 | -45 | N/A |
3/31/2023 | 0 | -48 | -39 | -39 | N/A |
12/31/2022 | 0 | -44 | -33 | -33 | N/A |
9/30/2022 | 0 | -42 | -33 | -33 | N/A |
6/30/2022 | 0 | -39 | -32 | -32 | N/A |
3/31/2022 | 0 | -40 | -32 | -32 | N/A |
12/31/2021 | 0 | -41 | -32 | -32 | N/A |
9/30/2021 | 0 | -37 | -34 | -34 | N/A |
6/30/2021 | 0 | -34 | -35 | -35 | N/A |
3/31/2021 | 0 | -31 | -29 | -29 | N/A |
12/31/2020 | -1 | -28 | -24 | -23 | N/A |
9/30/2020 | 0 | -20 | -17 | -17 | N/A |
6/30/2020 | N/A | -12 | -10 | -10 | N/A |
3/31/2020 | 2 | -14 | -10 | -10 | N/A |
12/31/2019 | 4 | -16 | -10 | -10 | N/A |
9/30/2019 | 3 | -16 | -8 | -8 | N/A |
6/30/2019 | 3 | -16 | -6 | -6 | N/A |
3/31/2019 | 3 | -11 | -7 | -7 | N/A |
12/31/2018 | 3 | -7 | -7 | -7 | N/A |
9/30/2018 | 3 | -7 | -6 | -6 | N/A |
6/30/2018 | 3 | -6 | -6 | -6 | N/A |
3/31/2018 | 2 | -6 | -5 | -4 | N/A |
12/31/2017 | 2 | -5 | -4 | -3 | N/A |
9/30/2017 | 2 | -5 | N/A | -4 | N/A |
6/30/2017 | 2 | -4 | N/A | -4 | N/A |
3/31/2017 | 2 | -4 | N/A | -5 | N/A |
12/31/2016 | 1 | -4 | N/A | -6 | N/A |
9/30/2016 | 1 | -4 | N/A | -5 | N/A |
6/30/2016 | 1 | -3 | N/A | -4 | N/A |
3/31/2016 | 1 | -3 | N/A | -3 | N/A |
12/31/2015 | 0 | -2 | N/A | -1 | N/A |
9/30/2015 | 0 | -2 | N/A | -1 | N/A |
6/30/2015 | N/A | -2 | N/A | -1 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PBIG.F is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.3%).
Earnings vs Market: PBIG.F is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: PBIG.F is expected to become profitable in the next 3 years.
Revenue vs Market: Insufficient data to determine if PBIG.F's revenue is forecast to grow faster than the US market.
High Growth Revenue: Insufficient data to determine if PBIG.F's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: PBIG.F's Return on Equity is forecast to be low in 3 years time (15.4%).